id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-1996-D-0048-0006,FDA,FDA-1996-D-0048,Guidance for Industry Q3B(R2) Impurities in New Drug Products,Other,Guidance,2021-10-27T04:00:00Z,2021,10,2021-10-27T04:00:00Z,,2021-10-27T16:06:56Z,,0,0,0900006484dfa462
FDA-1996-D-0048-0005,FDA,FDA-1996-D-0048,Q3B(R) Impurities in New Drug Products (Revision 2),Other,Guidance,2006-08-04T04:00:00Z,2006,8,2020-06-02T04:00:00Z,,2024-11-15T02:00:46Z,,1,0,09000064846c4e6f
FDA-1996-D-0048-0004,FDA,FDA-1996-D-0048,GUIDANCE,Supporting & Related Material,GDL-Guidance,2003-11-21T05:00:00Z,2003,11,,,2008-05-16T22:15:27Z,,0,0,09000064804fc7be
FDA-1996-D-0048-0003,FDA,FDA-1996-D-0048,GUIDANCE,Supporting & Related Material,GDL-Guidance,2003-11-21T05:00:00Z,2003,11,,,2008-05-16T22:15:26Z,,0,0,09000064804fc7bd
FDA-1996-D-0048-0002,FDA,FDA-1996-D-0048,FDA,Notice,NAD-Notice of Availability of Data,2003-11-21T05:00:00Z,2003,11,2003-11-13T05:00:00Z,,2008-05-16T22:15:27Z,,0,0,09000064804fc7bc
FDA-1996-D-0048-0001,FDA,FDA-1996-D-0048,HFM-40,Notice,NAD-Notice of Availability of Data,2000-07-19T04:00:00Z,2000,7,2000-07-19T04:00:00Z,2000-09-19T03:59:59Z,2008-05-16T22:15:27Z,,0,0,09000064804fc7a3